Form 4: Charles River Laboratories Director Acquires Common Stock and Stock Options

Craig B. Thompson, a Director at Charles River Laboratories International, Inc., reported the acquisition of 946 shares of common stock and 2,076 stock options.

Summary

• Craig B. Thompson, a Director of Charles River Laboratories International, Inc. (CRL), acquired 946 shares of common stock and 2,076 stock options on May 21, 2025.
• The common stock was acquired at a price of $134.98 per share.
• Following this transaction, Mr. Thompson directly beneficially owns 2,413 shares of common stock.
• The acquired stock options have an exercise price of $134.98 and are set to expire on May 21, 2035.
• Both the unvested restricted stock units (common stock) and stock options will vest or become exercisable upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase.

Sentiment

Score: 7

Explanation: The acquisition of shares and stock options by a director is generally a positive signal, indicating confidence in the company's future. However, it's a routine insider transaction, often pre-scheduled as part of compensation, and not a major strategic announcement that would significantly alter the company's outlook.

Positives

• A director acquiring shares and stock options can signal confidence in the company's future prospects and long-term value.
• The acquisition of stock options aligns the director's interests with long-term shareholder value creation, as their value is tied to the company's stock performance.
• The transaction being part of a Rule 10b5-1(c) plan indicates a structured and pre-planned acquisition, often part of compensation or long-term incentive programs.

Risks

• The full benefit of the acquired restricted stock units and stock options is not immediately realized, as they are subject to vesting conditions tied to future dates (May 21, 2026) or the company's next annual meeting of shareholders.

Future Outlook

The acquisition of unvested restricted stock units and stock options by a director suggests a long-term commitment and potential positive outlook, as the vesting and exercisability are tied to future dates, aligning the director's interests with the company's future performance and growth.

Management Comments

• The acquisition of shares and stock options by Director Craig B. Thompson, particularly under a Rule 10b5-1 plan, reflects a structured approach to compensation and a commitment to the company's long-term success.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity within the pharmaceutical and biotechnology services industry. Insider transactions are closely watched for signals regarding management's confidence in future growth and operational performance, especially for companies like Charles River Laboratories that provide critical research and development support to the life sciences sector.

Comparison to Industry Standards

• Insider acquisitions, particularly by directors, are generally viewed positively as they indicate alignment with shareholder interests, a common practice across industries.
• The use of restricted stock units and stock options as part of executive and director compensation is a standard practice in the life sciences and broader corporate sectors, aiming to incentivize long-term performance.
• The transaction being executed under a Rule 10b5-1 plan is a common and accepted method for insiders to trade company securities in a pre-arranged, compliant manner, consistent with corporate governance best practices.

Stakeholder Impact

• Shareholders: May interpret the director's acquisition as a positive sign of confidence in the company's future performance and alignment of interests.
• Management/Employees: Reinforces alignment between leadership and company success, potentially boosting morale and commitment.

Next Steps

• Vesting of restricted stock units and exercisability of stock options on or before May 21, 2026.
• The Company's next annual meeting of shareholders, which is a condition for the earlier vesting/exercisability of the securities.

Key Dates

Recommendation

Keywords

Charles River Laboratories, CRL, Form 4, Insider Trading, Stock Acquisition, Stock Options, Director, Craig B. Thompson, Beneficial Ownership, SEC Filing, Rule 10b5-1